Overview

The global Robotic Surgery Market was valued at USD 13.6 billion in 2025 and is projected to reach USD 42.5 billion by 2034, growing at a CAGR of 13.5% during the forecast period (2026-2034). The market growth is driven by rising adoption of minimally invasive procedures, growing demand for precision and accuracy in surgeries, increasing prevalence of chronic diseases, expanding investments in robotic surgical technologies. The market is shifting from a single-vendor, multi-port soft-tissue paradigm toward a multi-vendor, multi-format competitive landscape. Government initiatives are reinforcing this transformation. In the United States, ARPA-H launched its Autonomous Interventions and Robotics (AIR) program in November 2025 to develop autonomous and semi-autonomous robotic systems for stroke thrombectomy and other interventions, while the Centers for Medicare & Medicaid Services expanded ambulatory surgical center coverage for robotic procedures effective January 2026 and allocated Rural Health Transformation Fund grants, including USD 6.5 million to introduce robotic-assisted minimally invasive surgery in Southern Southeast Alaska. By region, North America held the dominant position in the Robotic Surgery Market in 2025, supported by high hospital capital investment, a dense installed base of da Vinci and Mako systems, and an active regulatory pipeline of new clearances. Asia-Pacific is projected to be the fastest-growing region during the forecast period, driven by expanding healthcare infrastructure, rising domestic manufacturing in China, Japan and South Korea, and growing government-backed adoption of robotic surgery in India.

Market Size & Share

Market Dynamics

KEY MARKET TREND:

AI-Enabled Multi-Vendor Competition Emerging as a Transformational Trend

• Hospitals are gaining access to a widening choice of AI-integrated soft-tissue robotic platforms as Medtronic's Hugo and CMR Surgical's Versius Plus received their first US FDA clearances in December 2025, ending Intuitive Surgical's two-decade-long exclusivity in the US soft-tissue segment.
• Platform developers are embedding AI-based navigation, motion analytics and imaging into next-generation consoles, exemplified by Intuitive's da Vinci 5 and Intuitive's Ion system, which added AI-powered navigation and nodule-tracking capability in 2025 and had approximately 900 systems installed across ten countries as of June 2025.
• Vendor diversification is prompting hospitals to plan multi-platform capital cycles and cross-platform proctoring frameworks, with professional surgical societies expected to issue credentialing guidance as adoption of Hugo, Versius Plus and Ottava expands during 2026.
• The U.S. Advanced Research Projects Agency for Health (ARPA-H) launched the Autonomous Interventions and Robotics (AIR) program on 20 November 2025 to develop autonomous and semi-autonomous robotic systems for stroke thrombectomy and other interventions, aiming to extend advanced surgical care beyond specialized medical centers nationwide.

 

KEY MARKET DRIVER:

Expanding Regulatory Clearances and Rising Chronic Disease Burden Driving Market Growth

• The growing global burden of chronic conditions, including urologic disorders, cancer and orthopedic degeneration, is increasing surgical volumes and the demand for minimally invasive, high-precision robotic-assisted procedures across hospitals and ambulatory settings.
• Regulatory momentum is accelerating platform adoption, with Intuitive Surgical receiving FDA clearance for nine new da Vinci 5 cardiac indications in 2026, including mitral and tricuspid valve repair, mitral valve replacement and left atrial appendage closure, and da Vinci SP indications expanded in December 2025 to include inguinal hernia repair, cholecystectomy and appendectomy.
• Hospitals are prioritizing capital investment in robotic platforms to reduce postoperative complications, blood loss and length of stay, reinforcing long-term cost advantages that support continued procurement despite high upfront system costs.
• Government initiatives such as the Union Budget 2026–27’s planned expansion of Robotic Surgery Centres in medical institutions, AIIMS Bhubaneswar’s commissioning of a comprehensive robotic surgery programme, and AIIMS Raipur’s government-backed robotic surgery facility are strengthening public healthcare infrastructure and expanding access to advanced surgical technologies.

 

KEY MARKET OPPORTUNITY:

Expansion into Ambulatory Surgical Centers and Underserved Regions Creates Significant Opportunity

• Compact, portable and handheld robotic formats, such as Stryker's Mako RPS and platforms from Distalmotion and Moon Surgical, are reducing operating-room footprint and capital requirements, opening adoption among ambulatory surgical centers and smaller community hospitals.
• The U.S. Centers for Medicare & Medicaid Services expanded the range of procedures ambulatory surgical centers may perform and bill for, effective 1 January 2026, creating a new outpatient site-of-service opportunity for robotic-assisted procedures.
• Government-backed rural and regional health investment is extending robotic surgery into underserved geographies, including a USD 6.5 million Rural Health Transformation Fund award to introduce the first robotic-assisted minimally invasive surgeries in Southern Southeast Alaska, and Himachal Pradesh's state-led plan to expand robotic surgical facilities to all public medical colleges by early 2026.
• Cross-border commercial partnerships, such as the collaboration between Ronovo Surgical and Johnson & Johnson MedTech announced in 2026 to expand access to surgical robotics technology in China, illustrate growing investment attractiveness in emerging robotic surgery markets.

Robotic Surgery Market Size, 2025-2034 (USD Billion)

Segmentation Analysis

Analysis by Component

Instruments held the largest market share in 2025 because robotic procedures require recurring, often single-use, articulating instruments, trocars, and accessory kits that are replaced across each procedure, generating a high-volume, high-frequency revenue stream that exceeds one-time capital system sales. Hospitals with an established installed base of systems continue to generate steady instrument and accessory demand, supported by expanding indications that require specialty-specific tooling for urology, gynecology, general surgery, and orthopedic applications.

 

Services are projected to grow at the fastest CAGR during the forecast period as hospitals increasingly adopt subscription-style and outcome-based service agreements covering system maintenance, software upgrades, and clinical training. The entry of new platform vendors is intensifying competition for post-installation service contracts, while national training initiatives such as the UK's Surgical Training in Advanced Robotic Technology (START) programme are expanding the market for standardized, platform-agnostic training services.

 

Component categories include

              ·           Instruments (Dominating Segment)

              ·           Services (Highest CAGR Segment)

              ·           Systems

 

Analysis by Application

Orthopedic surgery held the largest market share in 2025, supported by the wide hospital installed base of platforms such as Stryker's Mako, Zimmer Biomet's ROSA, and Smith+Nephew's CORI in knee and hip replacement procedures. Rising incidence of osteoarthritis, an aging global population, and strong clinical evidence for improved implant alignment and reduced revision rates continue to support high adoption of orthopedic robotic-assisted surgery across both academic and community hospitals.

 

General surgery is projected to grow at the fastest CAGR during the forecast period, driven by the entry of new soft-tissue platforms, including Medtronic's Hugo, CMR Surgical's Versius Plus, and Johnson & Johnson's Ottava, each targeting cholecystectomy, hernia repair, and colorectal procedures. Expanded da Vinci SP indications covering inguinal hernia repair, cholecystectomy, and appendectomy granted in December 2025 are further widening the addressable procedure base for general surgery.

 

Application categories include

              ·           Orthopaedic Surgery (Dominating Segment)

              ·           General Surgery (Highest CAGR Segment)

              ·           Urology

              ·           Gynaecology

              ·           Neurosurgery

              ·           Cardiothoracic Surgery

              ·           Others

 

Analysis by End User

Hospitals held the largest market share in 2025, accounting for a substantial share of global demand due to their advanced infrastructure, higher surgical case volumes, and capital investment capacity required to acquire and maintain robotic systems. Academic medical centers in particular continue to serve as primary adoption sites for newly cleared platforms, given their role in physician training and clinical evidence generation.

 

Ambulatory surgical centers are projected to grow at the fastest CAGR during the forecast period, supported by the US Centers for Medicare & Medicaid Services' expansion of the procedures ambulatory surgical centers may perform and bill for, effective January 2026, and by the entry of compact, lower-cost robotic platforms designed specifically for outpatient workflows.

 

End User categories include

              ·           Hospitals (Dominating Segment)

              ·           Ambulatory Surgical Centers (Highest CAGR Segment)

              ·           Specialty Clinics

 

Analysis by Type

Soft tissue robotic systems held the largest market share in 2025, led by Intuitive Surgical's da Vinci platform, which maintains the largest global installed base and clinical adoption across urology, gynecology, and general surgery. The high switching cost associated with surgeon training and hospital infrastructure built around established soft-tissue platforms continues to reinforce this segment's leadership position.

 

Orthopedic robotic systems are projected to grow at the fastest CAGR during the forecast period, supported by continued platform upgrades from Stryker, Zimmer Biomet, and Smith+Nephew, along with new entrants such as Monogram Technologies, acquired by Zimmer Biomet in October 2025 to expand its AI-driven orthopedic robotics and navigation portfolio.

 

Type categories include

              ·           Soft Tissue Robotic Systems (Dominating Segment)

              ·           Orthopedic Robotic Systems (Highest CAGR Segment)

              ·           Neurosurgical Robotic Systems

              ·           Endovascular Robotic Systems

              ·           Others

By Region

Robotic Surgery Market Regional Analysis

Regional Analysis

North America held the largest share of the Robotic Surgery Market in 2025, supported by advanced hospital infrastructure, high healthcare expenditure, and the concentration of leading manufacturers including Intuitive Surgical, Stryker, Medtronic, and Johnson & Johnson. The United States represented the largest country market, supported by the world's largest installed base of robotic systems, an active FDA regulatory pipeline, and CMS reimbursement changes expanding ambulatory surgical center access to robotic-assisted procedures from January 2026. Government-backed rural health investment, including Rural Health Transformation Fund awards, is extending robotic surgery access into underserved regions such as Alaska. Canada is witnessing steady adoption growth supported by public hospital capital programs and academic medical center partnerships, while Mexico is gradually expanding robotic surgery adoption through investments in advanced hospitals and specialist surgical centers. Europe maintains a strong market position, led by Germany, the United Kingdom, France, and Italy, supported by advanced healthcare systems, established regulatory frameworks, and growing adoption of robotic-assisted procedures, while the Rest of Europe is gradually increasing utilization across tertiary hospitals and specialized surgical centers.

 

Asia Pacific is projected to grow at the fastest CAGR during the forecast period, driven by expanding healthcare infrastructure investment, rising surgical volumes, and the emergence of domestic manufacturers including MicroPort MedBot, Medicaroid, Meere Company, and Ronovo Surgical. China is the fastest-growing country market, supported by accelerated commercialization, domestic robotic surgery development, and partnerships such as the 2026 collaboration between Ronovo Surgical and Johnson & Johnson MedTech to expand surgical robotics access. India is expanding public-sector adoption, supported by investments in advanced hospitals and the continued growth of domestic platform developer SS Innovations. Japan and South Korea maintain strong positions in precision manufacturing and hospital-based robotic adoption, supported by established regulatory frameworks and growing government interest in medical technology innovation, while the Rest of Asia Pacific is benefiting from increasing healthcare investment and the modernization of surgical facilities. Latin America is developing steadily, with Brazil representing the leading country market through its large healthcare system and concentration of advanced private hospitals, while Chile and the Rest of Latin America are gradually expanding access to robotic-assisted surgery. In the Middle East & Africa, Saudi Arabia and the United Arab Emirates are leading adoption through healthcare modernization programs, specialist hospitals, and investments in advanced surgical technologies, while the Rest of Middle East & Africa is progressing at an earlier stage.

 

Countries and Region covered

North America

o    United States (Largest Country Market)

o    Canada

o    Mexico

Europe

o    Germany

o    United Kingdom

o    France

o    Italy

o    Rest of Europe

Asia Pacific

o    China (Fastest-Growing Country Market)

o    India

o    Japan

o    South Korea

o    Rest of Asia Pacific

Latin America

o    Brazil

o    Chile

o    Rest of Latin America

Middle East & Africa

o    Saudi Arabia

o    United Arab Emirates

o    Rest of Middle East & Africa

Market Share

The market is consolidated, with Intuitive Surgical, Medtronic, Stryker, Zimmer Biomet, Smith+Nephew, CMR Surgical, MicroPort MedBot, SS Innovations, Distalmotion, Moon Surgical, Renishaw, THINK Surgical, meerecompany, Ronovo Surgical, and PROCEPT BioRobotics representing key manufacturers across soft-tissue, orthopedic, neurosurgical, urological, and robotic-assisted intervention applications. Intuitive Surgical maintains the largest global installed base and a strong market position built on more than two decades of clinical adoption, while competitors including Medtronic, CMR Surgical, and other emerging platform providers are increasing competition in soft-tissue robotic surgery. Large-cap players such as Stryker, Zimmer Biomet, and Smith+Nephew hold strong positions in orthopedic robotics, while emerging companies including Distalmotion, Moon Surgical, SS Innovations, MicroPort MedBot, Ronovo Surgical, and THINK Surgical are targeting flexible workflows, ambulatory settings, and regional markets. Key success factors include regulatory clearance breadth, installed base and surgeon training networks, instrument and service recurring revenue, and platform interoperability. Leading companies are prioritizing indication expansion, ambulatory surgical center strategies, AI-enabled navigation, and strategic partnerships or acquisitions, with Zimmer Biomet's October 2025 acquisition of Monogram Technologies strengthening its position in orthopedic robotic technology.

 

Key Players

           ·           Intuitive Surgical, Inc. (United States)

           ·           Medtronic plc (Ireland)

           ·           Stryker Corporation (United States)

           ·           Zimmer Biomet Holdings, Inc. (United States)

           ·           Smith+Nephew plc (United Kingdom)

           ·           CMR Surgical Limited (United Kingdom)

           ·           MicroPort MedBot (Group) Co., Ltd. (China)

           ·           SS Innovations International, Inc. (India)

           ·           Distalmotion SA (Switzerland)

           ·           Moon Surgical SAS (France)

           ·           Renishaw plc (United Kingdom)

           ·           THINK Surgical, Inc. (United States)

           ·           meerecompany Inc. (South Korea)

           ·           Ronovo Surgical Inc. (China)

           ·           PROCEPT BioRobotics Corporation (United States)

 

Recent Market Developments

• December 2025: Medtronic received FDA clearance for its Hugo robotic-assisted surgery system for urologic procedures, marking its first US soft-tissue indication after several years of international commercialization experience.
• December 2025: CMR Surgical secured FDA clearance for its Versius Plus soft-tissue platform for cholecystectomy procedures, with US commercialization now under way alongside Intuitive's expanded da Vinci SP indications covering inguinal hernia repair, cholecystectomy, and appendectomy.
• October 2025: Zimmer Biomet completed the acquisition of Monogram Technologies, Inc., an AI-driven orthopedic robotics company, to expand its robotics and navigation portfolio.
• January 2026: Johnson & Johnson submitted its Ottava surgical robot for FDA de novo authorization in general surgery, with positive pivotal study results reported in May 2026 and clearance pending.

Frequently Asked Questions